Balyasny Asset Management
ADMS

Balyasny Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Balyasny Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-35,748
Closed -$716K – 1896
2018
Q3 		$716K Buy
+35,748
New +$839K ﹤0.01% 1275
2018
Q1 		– Sell
-200,000
Closed -$6.78M – 2448
2017
Q4 		$6.78M Buy
+200,000
New +$5.58M 0.02% 756
2016
Q3 		– Sell
-20,152
Closed -$305K – 1356
2016
Q2 		$305K Sell
20,152
-10,968
-35% -$181K ﹤0.01% 917
2016
Q1 		$450K Buy
31,120
+22,590
+265% +$380K ﹤0.01% 908
2015
Q4 		$242K Buy
+8,530
New +$144K ﹤0.01% 1039

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Balyasny Asset Management's ADMS Position: Q4 2018 in Review

Balyasny Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 35,748 shares — an estimated $716K sold.

Balyasny Asset Management first reported a position in ADMS in Q4 2015 and held it in 5 quarters. The position peaked at $6.78M in Q4 2017. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • Balyasny Asset Management reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 35,748 Adamas Pharmaceuticals shares in Q4 2018, an estimated $716K.
  • Balyasny Asset Management first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Balyasny Asset Management's Adamas Pharmaceuticals position peaked at $6.78M in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Balyasny Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.